Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 943614, 8 pages
http://dx.doi.org/10.1155/2008/943614
Review Article

Renal and Vascular Mechanisms of Thiazolidinedione-Induced Fluid Retention

Department of Internal Medicine, University of Utah and Veterans Affairs Medical Center, Salt Lake City, UT 84132-2412, USA

Received 25 February 2008; Accepted 4 June 2008

Academic Editor: Jane Pinaire

Copyright © 2008 Tianxin Yang and Sunhapas Soodvilai. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Füchtenbusch, E. Standl, and H. Schatz, “Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus,” Experimental and Clinical Endocrinology & Diabetes, vol. 108, no. 3, pp. 151–163, 2000. View at Publisher · View at Google Scholar
  2. I. B. Hirsch, J. Kelly, and S. Cooper, “Pulmonary edema associated with troglitazone therapy,” Archives of Internal Medicine, vol. 159, no. 15, p. 1811, 1999. View at Publisher · View at Google Scholar
  3. M. L. Thomas and S. J. Lloyd, “Pulmonary edema associated with rosiglitazone and troglitazone,” The Annals of Pharmacotherapy, vol. 35, no. 1, pp. 123–124, 2001. View at Publisher · View at Google Scholar
  4. (Pioglitazone) PIA. Takeda Pharmaceuticals, Inc.
  5. (Rosiglitazone) PIA. GlaxoSmithKline Pharmaceuticals.
  6. S. Z. Duan, M. G. Usher, and R. M. Mortensen, “Peroxisome proliferator-activated receptor-γ-mediated effects in the vasculature,” Circulation Research, vol. 102, no. 3, pp. 283–294, 2008. View at Publisher · View at Google Scholar
  7. N. K. Hollenberg, “Considerations for management of fluid dynamic issues associated with thiazolidinediones,” The American Journal of Medicine, vol. 115, no. 8, supplement 1, pp. 111–115, 2003. View at Publisher · View at Google Scholar
  8. G. N. Kalambokis, A. A. Tsatsoulis, and E. V. Tsianos, “The edematogenic properties of insulin,” American Journal of Kidney Diseases, vol. 44, no. 4, pp. 575–590, 2004. View at Publisher · View at Google Scholar
  9. R. W. Nesto, D. Bell, R. O. Bonow et al., “Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association,” Circulation, vol. 108, no. 23, pp. 2941–2948, 2003. View at Publisher · View at Google Scholar
  10. N. V. Niemeyer and L. M. Janney, “Thiazolidinedione-induced edema,” Pharmacotherapy, vol. 22, no. 7, pp. 924–929, 2002. View at Publisher · View at Google Scholar
  11. A. Rubenstrunk, R. Hanf, D. W. Hum, J.-C. Fruchart, and B. Staels, “Safety issues and prospects for future generations of PPAR modulators,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1065–1081, 2007. View at Publisher · View at Google Scholar
  12. W. H. W. Tang and A. Maroo, “PPARγ agonists: safety issues in heart failure,” Diabetes, Obesity and Metabolism, vol. 9, no. 4, pp. 447–454, 2007. View at Publisher · View at Google Scholar
  13. J. Song, M. A. Knepper, X. Hu, J. G. Verbalis, and C. A. Ecelbarger, “Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 308, no. 2, pp. 426–433, 2004. View at Publisher · View at Google Scholar
  14. B. Yang, L. G. Clifton, J. A. McNulty, L. Chen, K. K. Brown, and P. G. Baer, “Effects of a PPARγ agonist, GI262570, on renal filtration fraction and nitric oxide level in conscious rats,” Journal of Cardiovascular Pharmacology, vol. 42, no. 3, pp. 436–441, 2003. View at Publisher · View at Google Scholar
  15. A. Zanchi, A. Chiolero, M. Maillard, J. Nussberger, H.-R. Brunner, and M. Burnier, “Effects of the peroxisomal proliferator-activated receptor-γ agonist pioglitazone on renal and hormonal responses to salt in healthy men,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 3, pp. 1140–1145, 2004. View at Publisher · View at Google Scholar
  16. M. A. Knepper, J. B. Wade, J. Terris et al., “Renal aquaporins,” Kidney International, vol. 49, no. 6, pp. 1712–1717, 1996. View at Publisher · View at Google Scholar
  17. J. Loffing, D. Loffing-Cueni, A. Macher et al., “Localization of epithelial sodium channel and aquaporin-2 in rabbit kidney cortex,” American Journal of Physiology, vol. 278, no. 4, pp. F530–F539, 2000. View at Google Scholar
  18. J. Loffing, L. Pietri, F. Aregger et al., “Differential subcellular localization of ENaC subunits in mouse kidney in response to high- and low-Na diets,” American Journal of Physiology, vol. 279, no. 2, pp. F252–F258, 2000. View at Google Scholar
  19. S. Masilamani, G.-H. Kim, C. Mitchell, J. B. Wade, and M. A. Knepper, “Aldosterone-mediated regulation of ENaC α, β, and γ subunit proteins in rat kidney,” The Journal of Clinical Investigation, vol. 104, no. 7, pp. R19–R23, 1999. View at Publisher · View at Google Scholar
  20. G. Hong, A. Lockhart, B. Davis et al., “PPAR? activation enhances cell surface ENaCa via up-regulation of SGK1 in human collecting duct cells,” The FASEB Journal, vol. 17, no. 3, pp. 1966–1968, 2003. View at Publisher · View at Google Scholar
  21. J. A. Schafer, “Abnormal regulation of ENaC: syndromes of salt retention and salt wasting by the collecting duct,” American Journal of Physiology, vol. 283, no. 2, pp. F221–F235, 2002. View at Google Scholar
  22. O. Staub and F. Verrey, “Impact of Nedd4 proteins and serum and glucocorticoid-induced kinases on epithelial Na+ transport in the distal nephron,” Journal of the American Society of Nephrology, vol. 16, no. 11, pp. 3167–3174, 2005. View at Publisher · View at Google Scholar
  23. Y. Guan, Y. Zhang, L. Davis, and M. D. Breyer, “Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans,” American Journal of Physiology, vol. 273, no. 6, pp. F1013–F1022, 1997. View at Google Scholar
  24. Y. Guan, Y. Zhang, A. Schneider, L. Davis, R. M. Breyer, and M. D. Breyer, “Peroxisome proliferator-activated receptor-γ activity is associated with renal microvasculature,” American Journal of Physiology, vol. 281, no. 6, pp. F1036–F1046, 2001. View at Google Scholar
  25. T. Yang, D. E. Michele, J. Park et al., “Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney,” American Journal of Physiology, vol. 277, no. 6, pp. F966–F973, 1999. View at Google Scholar
  26. L. Chen, B. Yang, J. A. McNulty et al., “GI262570, a peroxisome proliferator-activated receptor ? agonist, changes electrolytes and water reabsorption from the distal nephron in rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 312, no. 2, pp. 718–725, 2005. View at Publisher · View at Google Scholar
  27. Y. Guan, C. Hao, D. R. Cha et al., “Thiazolidinediones expand body fluid volume through PPAR? stimulation of ENaC-mediated renal salt absorption,” Nature Medicine, vol. 11, no. 8, pp. 861–866, 2005. View at Publisher · View at Google Scholar
  28. H. Zhang, A. Zhang, D. E. Kohan, R. D. Nelson, F. J. Gonzalez, and T. Yang, “Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 26, pp. 9406–9411, 2005. View at Publisher · View at Google Scholar
  29. C. Nofziger, L. Chen, M. A. Shane, C. D. Smith, K. K. Brown, and B. L. Blazer-Yost, “PPARγ agonists do not directly enhance basal or insulin-stimulated Na+ transport via the epithelial Na+ channel,” Pflügers Archiv: European Journal of Physiology, vol. 451, no. 3, pp. 445–453, 2005. View at Publisher · View at Google Scholar
  30. S. Mittra, G. Sangle, R. Tandon et al., “Increase in weight induced by muraglitazar, a dual PPARa/? agonist, in db/db mice: adipogenesis/or oedema?” British Journal of Pharmacology, vol. 150, no. 4, pp. 480–487, 2007. View at Publisher · View at Google Scholar
  31. V. Vallon, E. Hummler, T. Rieg et al., “Collecting duct-specific inactivation of aENaC in the mouse kidney does not attenuate rosiglitazone-induced weight gain,” The FASEB Journal, Meeting Abstract, vol. 22, 947.14, 2008. View at Google Scholar
  32. I. Rubera, J. Loffing, L. G. Palmer et al., “Collecting duct-specific gene inactivation of aENaC in the mouse kidney does not impair sodium and potassium balance,” The Journal of Clinical Investigation, vol. 112, no. 4, pp. 554–565, 2003. View at Publisher · View at Google Scholar
  33. C. L. Varley, M. A. E. Garthwaite, W. Cross, J. Hinley, L. K. Trejdosiewicz, and J. Southgate, “PPARγ-regulated tight junction development during human urothelial cytodifferentiation,” Journal of Cellular Physiology, vol. 208, no. 2, pp. 407–417, 2006. View at Publisher · View at Google Scholar
  34. D. Bishop-Bailey, “Peroxisome proliferator-activated receptors in the cardiovascular system,” British Journal of Pharmacology, vol. 129, no. 5, pp. 823–834, 2000. View at Publisher · View at Google Scholar
  35. I. Inoue, K. Shino, S. Noji, T. Awata, and S. Katayama, “Expression of peroxisome proliferator-activated receptor α (PPARα) in primary cultures of human vascular endothelial cells,” Biochemical and Biophysical Research Communications, vol. 246, no. 2, pp. 370–374, 1998. View at Publisher · View at Google Scholar
  36. H. Satoh, K. Tsukamoto, Y. Hashimoto et al., “Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPAR? on vascular endothelial function,” Biochemical and Biophysical Research Communications, vol. 254, no. 3, pp. 757–763, 1999. View at Publisher · View at Google Scholar
  37. B. Staels, W. Koenig, A. Habib et al., “Activation of human aortic smooth-muscle cells is inhibited by PPARa but not by PPAR? activators,” Nature, vol. 393, no. 6687, pp. 790–793, 1998. View at Publisher · View at Google Scholar
  38. G. Chinetti, S. Griglio, M. Antonucci et al., “Activation of proliferator-activated receptors a and ? induces apoptosis of human monocyte-derived macrophages,” Journal of Biological Chemistry, vol. 273, no. 40, pp. 25573–25580, 1998. View at Publisher · View at Google Scholar
  39. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar
  40. M. J. Ryan, S. P. Didion, S. Mathur, F. M. Faraci, and C. D. Sigmund, “PPARγ agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice,” Hypertension, vol. 43, no. 3, pp. 661–666, 2004. View at Publisher · View at Google Scholar
  41. H. F. Dvorak, J. A. Nagy, D. Feng, L. F. Brown, and A. M. Dvorak, “Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis,” Current Topics in Microbiology and Immunology, vol. 237, pp. 97–132, 1999. View at Google Scholar
  42. I. Baumgartner, G. Rauh, A. Pieczek et al., “Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor,” Annals of Internal Medicine, vol. 132, no. 11, pp. 880–884, 2000. View at Google Scholar
  43. L. L. H. Peeters, J.-L. Vigne, M. K. Tee, D. Zhao, L. L. Waite, and R. N. Taylor, “PPARγ represses VEGF expression in human endometrial cells: implications for uterine angiogenesis,” Angiogenesis, vol. 8, no. 4, pp. 373–379, 2006. View at Publisher · View at Google Scholar
  44. T. L. Sander, L. A. Noll, D. B. Klinkner et al., “Rosiglitazone antagonizes vascular endothelial growth factor signaling and nuclear factor of activated T cells activation in cardiac valve endothelium,” Endothelium, vol. 13, no. 3, pp. 181–190, 2006. View at Publisher · View at Google Scholar
  45. W. H.-H. Sheu, H.-C. Ou, F.-P. Chou, T.-M. Lin, and C.-H. Yang, “Rosiglitazone inhibits endothelial proliferation and angiogenesis,” Life Sciences, vol. 78, no. 13, pp. 1520–1528, 2006. View at Publisher · View at Google Scholar
  46. J. A. Polikandriotis, L. J. Mazzella, H. L. Rupnow, and C. M. Hart, “Peroxisome proliferator-activated receptor γ ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor γ-dependent mechanisms,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 9, pp. 1810–1816, 2005. View at Publisher · View at Google Scholar
  47. P. St-Pierre, L. Bouffard, and P. Maheux, “Rosiglitazone increases extravasation of macromolecules and endothelial nitric oxide synthase in skeletal muscles of the fructose-fed rat model,” Biochemical Pharmacology, vol. 67, no. 10, pp. 1997–2004, 2004. View at Publisher · View at Google Scholar
  48. H. Clarke, C. W. Marano, A. P. Soler, and J. M. Mullin, “Modification of tight junction function by protein kinase C isoforms,” Advanced Drug Delivery Reviews, vol. 41, no. 3, pp. 283–301, 2000. View at Publisher · View at Google Scholar
  49. H. Clarke, A. P. Soler, and J. M. Mullin, “Protein kinase C activation leads to dephosphorylation of occludin and tight junction permeability increase in LLC-PK1 epithelial cell sheets,” Journal of Cell Science, vol. 113, no. 18, pp. 3187–3196, 2000. View at Google Scholar
  50. J. E. Stasek Jr. and J. G. N. Garcia, “The role of protein kinase C in α-thrombin-mediated endothelial cell activation,” Seminars in Thrombosis and Hemostasis, vol. 18, no. 1, pp. 117–125, 1992. View at Google Scholar
  51. J. E. Stasek Jr., C. E. Patterson, and J. G. N. Garcia, “Protein kinase C phosphorylates caldesmon77 and vimentin and enhances albumin permeability across cultured bovine pulmonary artery endothelial cell monolayers,” Journal of Cellular Physiology, vol. 153, no. 1, pp. 62–75, 1992. View at Publisher · View at Google Scholar
  52. K. B. Sotiropoulos, A. Clermont, Y. Yasuda et al., “Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPAR? agonist's effects on edema and weight gain,” The FASEB Journal, vol. 20, no. 8, pp. 1203–1205, 2006. View at Publisher · View at Google Scholar
  53. F. Wang, L. M. Aleksunes, L. A. Reagan, and C. M. Vergara, “Management of rosiglitazone-induced edema: two case reports and a review of the literature,” Diabetes Technology & Therapeutics, vol. 4, no. 4, pp. 505–514, 2002. View at Publisher · View at Google Scholar
  54. J. Karalliedde, R. Buckingham, M. Starkie, D. Lorand, M. Stewart, and G. Viberti, “Effect of various diuretic treatments on rosiglitazone-induced fluid retention,” Journal of the American Society of Nephrology, vol. 17, no. 12, pp. 3482–3490, 2006. View at Publisher · View at Google Scholar
  55. D. H. Ellison, H. Velazquez, and F. S. Wright, “Thiazide-sensitive sodium chloride cotransport in early distal tubule,” American Journal of Physiology, vol. 253, no. 3, pp. F546–F554, 1987. View at Google Scholar
  56. F. A. Gesek and P. A. Friedman, “Sodium entry mechanisms in distal convoluted tubule cells,” American Journal of Physiology, vol. 268, no. 1, pp. F89–F98, 1995. View at Google Scholar
  57. D. R. Wilson, U. Honrath, and H. Sonnenberg, “Thiazide diuretic effect on medullary collecting duct function in the rat,” Kidney International, vol. 23, no. 5, pp. 711–716, 1983. View at Publisher · View at Google Scholar
  58. C. Bailly, “Transducing pathways involved in the control of NaCl reabsorption in the thick ascending limb of Henle's loop,” Kidney International. Supplement, vol. 65, pp. S29–S35, 1998. View at Google Scholar
  59. G. Boden, C. Homko, M. Mozzoli, M. Zhang, K. Kresge, and P. Cheung, “Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention,” Diabetes, vol. 56, no. 1, pp. 248–255, 2007. View at Publisher · View at Google Scholar
  60. G. Boden and M. Zhang, “Recent findings concerning thiazolidinediones in the treatment of diabetes,” Expert Opinion on Investigational Drugs, vol. 15, no. 3, pp. 243–250, 2006. View at Publisher · View at Google Scholar
  61. G. J. Etgen, B. A. Oldham, W. T. Johnson et al., “A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-a/? agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models,” Diabetes, vol. 51, no. 4, pp. 1083–1087, 2002. View at Publisher · View at Google Scholar
  62. S. E. Nissen, K. Wolski, and E. J. Topol, “Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus,” Journal of the American Medical Association, vol. 294, no. 20, pp. 2581–2586, 2005. View at Publisher · View at Google Scholar
  63. P. W. Anderson, J. B. McGill, and K. R. Tuttle, “Protein kinase C β inhibition: the promise for treatment of diabetic nephropathy,” Current Opinion in Nephrology and Hypertension, vol. 16, no. 5, pp. 397–402, 2007. View at Publisher · View at Google Scholar
  64. M. Clarke and P. M. Dodson, “PKC inhibition and diabetic microvascular complications,” Best Practice & Research in Clinical Endocrinology & Metabolism, vol. 21, no. 4, pp. 573–586, 2007. View at Publisher · View at Google Scholar